Lv4
570 积分 2022-02-17 加入
758P Concordance between multiple HRD assays is substantial in high-grade ovarian cancer
7小时前
待确认
Prognostic Value of Immunohistochemistry-based Subtyping Before and After Neoadjuvant Chemotherapy in Patients with Triple-negative Breast Cancer
7小时前
已完结
Clinical significance of homologous recombination deficiency score testing in endometrial Cancer
7小时前
待确认
A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial
8小时前
待确认
Breast cancer
8小时前
已完结
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
27天前
已完结
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial
27天前
已完结
MRI-based Quantification of Intratumoral Heterogeneity for Predicting Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer
2个月前
已完结
Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial
2个月前
已完结
Nanodiamond-Mediated Targeted Delivery of Nanobodies and Immunostimulatory RNA for Breast Cancer Therapy
2个月前
已完结
皖公网安备34019202002308
